The identification of HER2 as an important oncogene in breast cancer led to the development of anti-HER2 therapies such as the monoclonal antibody trastuzumab (Herceptin®) or the small tyrosine kinase inhibitor lapatinib. This evidence concerns the gene ERBB2 and breast cancer.